CA2744997A1 - C-met modulators and method of use - Google Patents

C-met modulators and method of use Download PDF

Info

Publication number
CA2744997A1
CA2744997A1 CA2744997A CA2744997A CA2744997A1 CA 2744997 A1 CA2744997 A1 CA 2744997A1 CA 2744997 A CA2744997 A CA 2744997A CA 2744997 A CA2744997 A CA 2744997A CA 2744997 A1 CA2744997 A1 CA 2744997A1
Authority
CA
Canada
Prior art keywords
optionally substituted
quinolin
phenyl
fluoro
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2744997A
Other languages
English (en)
French (fr)
Inventor
Lynne Canne Bannen
Diva Sze-Ming Chan
Jeff Chen
Lisa Esther Dalrymple
Timothy Patrick Forsyth
Tai Phat Huynh
Vasu Jammalamadaka
Richard George Khoury
James William Leahy
Morrison B. Mac
Grace Mann
Larry W. Mann
John M. Nuss
Jason Jevious Parks
Craig Stacy Takeuchi
Yong Wang
Wei Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34397024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2744997(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CA2744997A1 publication Critical patent/CA2744997A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
CA2744997A 2003-09-26 2004-09-24 C-met modulators and method of use Abandoned CA2744997A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US50618103P 2003-09-26 2003-09-26
US60/506,181 2003-09-26
US53537704P 2004-01-09 2004-01-09
US60/535,377 2004-01-09
US57738404P 2004-06-04 2004-06-04
US60/577,384 2004-06-04
CA2537812A CA2537812C (en) 2003-09-26 2004-09-24 C-met modulators and method of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2537812A Division CA2537812C (en) 2003-09-26 2004-09-24 C-met modulators and method of use

Publications (1)

Publication Number Publication Date
CA2744997A1 true CA2744997A1 (en) 2005-04-07

Family

ID=34397024

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2744997A Abandoned CA2744997A1 (en) 2003-09-26 2004-09-24 C-met modulators and method of use
CA2537812A Expired - Lifetime CA2537812C (en) 2003-09-26 2004-09-24 C-met modulators and method of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2537812A Expired - Lifetime CA2537812C (en) 2003-09-26 2004-09-24 C-met modulators and method of use

Country Status (19)

Country Link
US (14) US9174947B2 (enExample)
EP (9) EP2392564B1 (enExample)
JP (14) JP4638436B2 (enExample)
AT (3) ATE517091T1 (enExample)
AU (3) AU2004275842B2 (enExample)
BE (1) BE2014C055I2 (enExample)
CA (2) CA2744997A1 (enExample)
CY (3) CY1111956T1 (enExample)
DK (4) DK2392564T3 (enExample)
ES (6) ES2436888T3 (enExample)
FR (1) FR14C0067I2 (enExample)
HR (4) HRP20110707T1 (enExample)
HU (1) HUS1400052I1 (enExample)
LU (1) LU92508I2 (enExample)
NL (1) NL300678I2 (enExample)
PL (3) PL2392565T3 (enExample)
PT (2) PT2210607E (enExample)
SI (4) SI2213661T1 (enExample)
WO (1) WO2005030140A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605391A (zh) * 2022-02-21 2022-06-10 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用

Families Citing this family (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3366959B2 (ja) 1998-06-19 2003-01-14 三洋昭和パネルシステム株式会社 高さ調整自在な幅木
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
ATE352550T1 (de) 2003-09-19 2007-02-15 Astrazeneca Ab Chinazolinderivate
ES2436888T3 (es) * 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
WO2005073224A2 (en) * 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
CN1906167A (zh) * 2004-02-27 2007-01-31 卫材株式会社 新型吡啶衍生物及嘧啶衍生物(2)
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
AU2005286846A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006040520A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinazoline derivatives
ES2450566T3 (es) * 2004-11-30 2014-03-25 Amgen Inc. Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
EP1674466A1 (en) * 2004-12-27 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
KR20080026562A (ko) * 2005-06-02 2008-03-25 갤럭시 바이오테크, 엘엘씨 항체를 이용한 뇌종양 치료 방법
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
BRPI0616799B8 (pt) 2005-08-24 2021-05-25 Eisai R&D Man Co Ltd derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
TW200806675A (en) * 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP5328640B2 (ja) 2006-04-19 2013-10-30 ノバルティス アーゲー ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
AU2007253950B2 (en) 2006-05-19 2012-05-03 Abbott Laboratories CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
WO2008021781A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
KR101380444B1 (ko) * 2006-08-23 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 페녹시피리딘 유도체의 염 또는 그 결정 및 이들의 제조 방법
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
JP2010507618A (ja) * 2006-10-27 2010-03-11 グラクソ グループ リミテッド ｃ−Ｍｅｔキナーゼ阻害薬としての７−アザインドール誘導体
CA2669991C (en) 2006-11-22 2016-01-26 Incyte Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
US7915287B2 (en) * 2006-12-20 2011-03-29 Amgen Inc. Substituted heterocycles and methods of use
WO2008088881A1 (en) * 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
US8293769B2 (en) * 2007-05-21 2012-10-23 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
WO2009021965A2 (en) 2007-08-15 2009-02-19 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
ES2635131T3 (es) 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
ES2547406T3 (es) 2008-03-17 2015-10-06 Ambit Biosciences Corporation Derivados de moduladores como moduladores de quinasas RAF y metodo de uso de los mismos
TWI438193B (zh) 2008-04-10 2014-05-21 Taiho Pharmaceutical Co Ltd 醯基硫脲化合物或其鹽、及其用途
US9206130B2 (en) * 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CA2724742C (en) 2008-05-21 2016-07-19 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
NZ590283A (en) 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
EP2149565A1 (de) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
CA2731323A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
AR075084A1 (es) * 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
WO2010045095A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
MX2011005038A (es) * 2008-11-13 2011-06-16 Exelisis Inc Metodo de preparacion de derivados de quinolina.
EP2367795A1 (en) * 2008-12-04 2011-09-28 Exelixis, Inc. Methods of preparing quinoline derivatives
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
CA2995880C (en) * 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
CA2752421C (en) 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
EP2440519A1 (en) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
TW201118072A (en) * 2009-07-17 2011-06-01 Exelixis Inc Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102030705B (zh) * 2009-09-30 2012-12-19 上海睿智化学研究有限公司 7-苄氧基-6-甲氧基-4-羟基喹啉的合成方法
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2501233B1 (en) * 2009-11-03 2014-09-24 GlaxoSmithKline LLC Quinazoline compounds
CA2782127A1 (en) * 2009-11-27 2011-06-03 Proteologics, Ltd. Quinazolin-4(3a)-one derivatives and methods of use thereof
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CN102086211B (zh) * 2009-12-08 2013-09-11 广东东阳光药业有限公司 作为蛋白激酶抑制剂的芳杂环化合物
ES2608329T3 (es) 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
JP2013522232A (ja) 2010-03-12 2013-06-13 エグゼリクシス， インコーポレイテッド Ｎ−［３−フルオロ−４−（｛６−（メチロキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボサミドの水和結晶性形状
WO2011117741A2 (en) * 2010-03-26 2011-09-29 EastNets Mobile remittance computer system and method
CN102212062B (zh) * 2010-04-02 2015-04-29 广东东阳光药业有限公司 氨基酯类衍生物及其盐和使用方法
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011139891A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
IL224189A (en) * 2010-07-16 2017-07-31 Exelixis Inc C-met modulator pharmaceutical compositions
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
JP6158705B2 (ja) * 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
EP2621482A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CA2812744A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2643001A4 (en) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
KR20210147117A (ko) 2011-02-10 2021-12-06 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
US20120252840A1 (en) * 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
CA2845933C (en) 2011-09-06 2020-06-09 New York Blood Center, Inc. Hiv inhibitors
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
CA2848512A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
MX343288B (es) * 2011-10-20 2016-11-01 Exelixis Inc Proceso para la preparación de derivados de quinolina.
US8843421B2 (en) 2011-11-01 2014-09-23 Accenture Global Services Limited Identification of entities likely to engage in a behavior
EP2775921A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Method of quantifying cancer treatment
US20140323522A1 (en) 2011-11-08 2014-10-30 Exelixis, Inc. Method of Treating Cancer
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103172641B (zh) * 2011-12-20 2014-06-11 钱卫 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
CN102643268B (zh) * 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
EP2620869B1 (en) 2012-01-27 2017-11-01 Optim Corporation Portable terminal, method, and program of changing user interface
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
BR112014024251A8 (pt) 2012-03-30 2018-01-23 Rhizen Pharmaceuticals S A novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2844254A1 (en) 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
WO2013180128A1 (ja) * 2012-05-28 2013-12-05 協和発酵キリン株式会社 4-[4-(5員環芳香族複素環カルボニルウレイド)フェニルオキシ]キノリン誘導体
CN103509024B (zh) * 2012-06-28 2015-10-28 上海医药工业研究院 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
CN103626762B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其应用
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN103705521A (zh) * 2012-09-28 2014-04-09 韩冰 一类治疗脑梗塞的化合物及其用途
CN103804305A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN102977014B (zh) * 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103804381A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804290A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804298A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804306A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
CN103804362A (zh) * 2012-11-12 2014-05-21 韩文毅 一类治疗糖尿病的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN102964308B (zh) * 2012-11-30 2015-03-18 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN103965104B (zh) * 2013-01-29 2017-09-29 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
WO2014145693A1 (en) * 2013-03-15 2014-09-18 Exelixis, Inc. Metabolites of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
BR112015023109A2 (pt) * 2013-03-15 2018-05-15 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida
RU2015141592A (ru) * 2013-03-15 2017-04-21 Ф. Хоффманн-Ля Рош Аг АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN108472242A (zh) 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
CN104109124B (zh) * 2013-04-19 2016-08-31 正大天晴药业集团股份有限公司 卡博替尼·0.5苹果酸盐的晶体
CN104109128B (zh) * 2013-04-19 2016-10-05 连云港润众制药有限公司 卡博替尼苹果酸盐及其制备方法
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104370811B (zh) * 2013-08-15 2019-02-12 广东东阳光药业有限公司 一种喹啉化合物的新晶型及其制备方法
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CA2940272C (en) 2014-02-28 2022-03-29 Tohoku University Amide derivative
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
BR112016024672A2 (pt) * 2014-04-25 2021-02-02 Exelixis, Inc método para o tratamento de adenocarcinoma de pulmão
WO2015177758A1 (en) 2014-05-23 2015-11-26 Mylan Laboratories Ltd Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) * 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
WO2016044808A1 (en) 2014-09-19 2016-03-24 New York Blood Center, Inc. Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv
CA2969540C (en) 2014-12-02 2023-03-21 Ignyta, Inc. Combinations for the treatment of neuroblastoma
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016150966A1 (en) 2015-03-25 2016-09-29 Sandoz Ag Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
US20170020856A1 (en) * 2015-06-29 2017-01-26 Ontogenesis, Llc N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use
CN107646030A (zh) * 2015-08-19 2018-01-30 桑多斯股份公司 丙二酸酯衍生物的不对称双酰胺化
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
CN105218445B (zh) * 2015-08-25 2018-05-22 江苏中邦制药有限公司 一种酪氨酸激酶抑制剂Foretinib的制备方法
CN106543143B (zh) * 2015-09-22 2019-03-22 合肥中科普瑞昇生物医药科技有限公司 一类新型的flt3激酶抑制剂及其用途
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN105541798B (zh) * 2016-02-03 2018-01-23 中国人民解放军第二军医大学 具有抗肿瘤活性的喹啉类多靶点激酶抑制剂及其制备方法
CN107129465B (zh) * 2016-02-26 2020-06-19 中国科学院上海药物研究所 芳基胍类化合物及其制备方法和用途
EP3436462A1 (en) * 2016-03-31 2019-02-06 Merck Patent GmbH Compounds for the inhibition of cyclophilins and uses thereof
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CN105906568A (zh) * 2016-04-28 2016-08-31 西安交通大学 一种具有抗肿瘤活性的环丙二酰胺化合物及其制备方法和应用
CN106083715A (zh) * 2016-06-01 2016-11-09 谢阳 一种喹啉、喹唑啉类化合物及其药物组合物和应用
CN106008371A (zh) * 2016-06-24 2016-10-12 谢阳 1-芳基脲基环烷基-1-甲酰胺类化合物及其药物组合物和应用
CN107556238A (zh) * 2016-06-30 2018-01-09 深圳万乐药业有限公司 一种卡博替尼的合成方法
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
CN109922790B (zh) * 2016-09-12 2022-06-14 珠海贝海生物技术有限公司 卡博替尼制剂
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
CA3038500A1 (en) 2016-09-27 2018-04-05 Andrea B. Apolo Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CA3040788C (en) * 2016-10-18 2022-01-11 Beijing Konruns Pharmaceutical Co., Ltd. Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
CN106632028B (zh) * 2016-12-22 2019-01-22 上海再启生物技术有限公司 一种卡博替尼的制备方法
CN108329298A (zh) * 2017-01-17 2018-07-27 南昌弘益药业有限公司 一类喹啉类新化合物制备方法
CA3049452A1 (en) 2017-01-20 2018-07-26 Gisela Schwab Combinations of cabozantinib and atezolizumab to treat cancer
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
KR102323255B1 (ko) 2017-02-15 2021-11-08 다이호야쿠힌고교 가부시키가이샤 의약 조성물
CN108503650B (zh) * 2017-02-27 2021-02-12 北京赛特明强医药科技有限公司 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
JP7117323B2 (ja) * 2017-04-27 2022-08-12 アストラゼネカ・アクチエボラーグ フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN110621662B (zh) 2017-05-26 2023-06-23 埃克塞里艾克西斯公司 一种盐的结晶性固体形式、制备工艺和使用方法
MX2019014298A (es) 2017-06-09 2020-02-03 Exelixis Inc Formas de dosificacion liquida para tratar el cancer.
MY201080A (en) 2017-07-14 2024-02-03 Innate Tumor Immunity Inc Nlrp3 modulators
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
SG11202001664VA (en) * 2017-08-31 2020-03-30 Abbvie Inc Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
AU2018329881B2 (en) 2017-09-08 2021-12-02 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect potentiator
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
CN111491920B (zh) 2017-10-20 2024-01-30 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US11352344B2 (en) 2017-10-31 2022-06-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN109824587A (zh) * 2017-11-23 2019-05-31 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂xjf007及其中间体的制备方法
CN109896997A (zh) * 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
WO2019125798A1 (en) * 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Carbamate and urea compounds as multikinase inhibitors
US20190262330A1 (en) * 2017-12-21 2019-08-29 Exelixis, Inc. Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
US11542259B2 (en) * 2018-01-26 2023-01-03 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
BR112020015199A2 (pt) * 2018-01-26 2021-05-04 Exelixis, Inc. compostos para o tratamento de distúrbios dependentes de quinase
CA3088198A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CA3090130A1 (en) 2018-02-02 2019-08-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN108264482A (zh) * 2018-02-05 2018-07-10 南京法恩化学有限公司 一种卡博替尼的制备方法
EP3750893B1 (en) 2018-02-11 2023-04-19 Beijing Scitech-MQ Pharmaceuticals Limited Dioxazoline compound, preparation method therefor, and uses thereof
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
US11498902B2 (en) 2018-06-05 2022-11-15 Natco Pharma Limited Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
US11702425B2 (en) * 2018-08-01 2023-07-18 Agency For Science, Technology And Research Bicyclic compounds as kinase modulators, methods and uses thereof
CN110862398B (zh) * 2018-08-27 2021-04-06 北京赛特明强医药科技有限公司 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
WO2020075196A1 (en) 2018-10-11 2020-04-16 Cipla Limited Polymorphs of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (s)- malate, methods of production and pharmaceutical uses thereof
CN111303024B (zh) 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
IL283860B2 (en) * 2018-12-13 2025-10-01 Exelixis Inc Crystalline forms and salt forms of kinase inhibitor
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION
JP7556865B2 (ja) * 2019-01-25 2024-09-26 エグゼリクシス， インコーポレイテッド キナーゼ依存性障害の治療のための化合物
CN109776432B (zh) * 2019-03-21 2020-07-24 广州六顺生物科技股份有限公司 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
JP7568641B2 (ja) * 2019-04-12 2024-10-16 ナショナル ヘルス リサーチ インスティトゥーツ 治療的使用のためのキナーゼ阻害剤としての複素環式化合物
CN111825609A (zh) * 2019-04-22 2020-10-27 北京康辰药业股份有限公司 化合物晶型、其制备方法、药物组合物以及应用
US20230052703A1 (en) * 2019-06-03 2023-02-16 Exelixis, Inc. Salt Forms of a Kinase Inhibitor
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CN110117254B (zh) * 2019-06-20 2022-05-13 江苏君若药业有限公司 卡博替尼的制备方法
CN112390749B (zh) * 2019-08-19 2024-12-03 鲁南制药集团股份有限公司 一种卡博替尼及其中间体的合成方法
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
CN111393363B (zh) * 2020-04-27 2022-12-20 威海海洋生物医药产业技术研究院有限公司 4-苯氧基喹啉并n-磺酰脒类化合物及其制备方法和用途
CN113577066B (zh) * 2020-04-30 2022-12-16 中国科学院上海药物研究所 芳基胍化合物或其药学上可接受的盐的用途
IT202000027678A1 (it) 2020-11-18 2022-05-18 Indena Spa Dispersioni solide amorfe di cabozantinib-(s)-malato e processi per la loro preparazione
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
UY39569A (es) * 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
BR112023019422A2 (pt) * 2021-03-24 2023-10-24 Biocon Ltd Processo de preparação de cabozantinibe
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
CN118339144A (zh) * 2021-12-03 2024-07-12 湖南湘源美东医药科技有限公司 卡博替尼共晶及制备方法以及作为药物或在药物制剂中的应用
CA3245315A1 (en) 2022-03-01 2023-09-07 Synthon Bv L(+) TARTARIC ACID CABOZANTINIB SALT AND ITS SOLID FORMS
WO2023222946A1 (en) 2022-05-18 2023-11-23 Fermion Oy Process for the preparation of cabozantinib
CN119255825A (zh) 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
EP4622961A1 (en) 2022-11-25 2025-10-01 Synthon B.V. A process for preparation of cabozantinib or tivozanib
CN120239695A (zh) * 2022-12-01 2025-07-01 江苏奥赛康药业有限公司 一种制备卡博替尼及其中间体的方法
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途
IL316197A (en) * 2023-10-17 2025-05-01 Great Novel Therapeutics Biotech & Medicals Corp Tyrosine kinase inhibitors and their uses
CN117843713A (zh) * 2023-12-18 2024-04-09 上海亲合力生物医药科技股份有限公司 基于肿瘤微环境激活的激酶抑制剂、组合物及应用

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US506181A (en) 1893-10-03 Folding crate
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US5123951A (en) * 1986-03-31 1992-06-23 Rhone-Poulenc Nederland B.V. Synergistic plant growth regulator compositions
JPS646261A (en) * 1987-03-31 1989-01-10 Nisshin Flour Milling Co 4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5034393A (en) * 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
US5238951A (en) * 1991-02-01 1993-08-24 E. R. Squibb & Sons, Inc. Heterocyclic amido prostaglandin analogs
DE4114733A1 (de) * 1991-05-06 1992-11-12 Huels Chemische Werke Ag Verfahren zur herstellung von substituierten malonesteraniliden und malonsaeure-monoaniliden
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
JPH11507052A (ja) * 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
BR9707495A (pt) * 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
WO1997034876A1 (en) * 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
EP0892789B2 (en) * 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
AR007857A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP2001500890A (ja) * 1996-09-25 2001-01-23 ゼネカ リミテッド Ｖｅｇｆのような成長因子の作用を阻害するキノリン誘導体
JP4073961B2 (ja) * 1996-10-01 2008-04-09 協和醗酵工業株式会社 含窒素複素環化合物
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
JP4303792B2 (ja) 1997-04-18 2009-07-29 協和発酵キリン株式会社 キノロン誘導体の製造方法
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
GB9708917D0 (en) 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6294532B1 (en) * 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
JP4194678B2 (ja) * 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2333392A1 (en) * 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
CN1152031C (zh) * 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1143950B1 (de) 1998-09-10 2005-03-09 BioEqual AG Topisch anwendbare mittel gegen nagelpilzerkrankungen
EA004436B1 (ru) 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
ES2191462T3 (es) 1998-10-01 2003-09-01 Astrazeneca Ab Derivados de quinolina y quinazolina y su uso como inhibidores de enfermedades mediadas por citoquinas.
ATE294796T1 (de) 1998-10-08 2005-05-15 Astrazeneca Ab Chinazolin derivate
EA003786B1 (ru) * 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
AU771504B2 (en) * 1999-01-22 2004-03-25 Kyowa Hakko Kirin Co., Ltd. Quinoline derivatives and quinazoline derivatives
PL199802B1 (pl) 1999-02-10 2008-10-31 Astrazeneca Ab Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
GB9904103D0 (en) * 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
AU3630100A (en) 1999-03-19 2000-10-09 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
EP1194418A1 (de) * 1999-06-21 2002-04-10 Boehringer Ingelheim Pharma KG Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CZ20021009A3 (cs) * 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003518023A (ja) * 1999-11-30 2003-06-03 パーカー ヒューズ インスティテュート トロンビン誘導血小板凝集の阻害剤
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
WO2001047890A1 (en) * 1999-12-24 2001-07-05 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
JP2003520855A (ja) * 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
US6664390B2 (en) 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
US7091227B2 (en) * 2000-02-07 2006-08-15 Abbott Gmbh & Co. Kg Benzothiazole derivatives
KR20080009294A (ko) 2000-03-13 2008-01-28 와이어쓰 홀딩스 코포레이션 시아노퀴놀린을 포함하는 결장 폴립의 치료 또는 억제를위한 약제학적 조성물
US6608048B2 (en) * 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
MXPA02011974A (es) 2000-06-28 2004-09-06 Astrazeneca Ab Derivados de quinazolina sustituidos y su uso como inhibidores.
EP1174118A1 (de) 2000-06-28 2002-01-23 Cognis France S.A. Verwendung von Inulinen und Inulinderivaten
FR2811658B1 (fr) 2000-07-17 2004-07-02 Cfpi Nufarm Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides
JP2002030083A (ja) * 2000-07-18 2002-01-29 Kirin Brewery Co Ltd Ｎ−（２−クロロ−４−｛［６−メトキシ−７−（３−ピリジルメトキシ）−４−キノリル］オキシ｝フェニル）−ｎ’−プロピルウレアの二塩酸塩
US7427689B2 (en) * 2000-07-28 2008-09-23 Georgetown University ErbB-2 selective small molecule kinase inhibitors
CZ2003486A3 (cs) 2000-08-21 2003-05-14 Astrazeneca Ab Chinazolinové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6403580B1 (en) * 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
WO2002034744A1 (en) 2000-10-25 2002-05-02 Astrazeneca Ab Quinazoline derivatives
WO2002044166A1 (en) 2000-11-02 2002-06-06 Astrazeneca Ab Substituted quinolines as antitumor agents
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
EP1340748B1 (en) 2000-11-02 2008-01-16 Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
BRPI0209216B8 (pt) 2001-04-27 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
US6734303B2 (en) * 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
DE10125432A1 (de) * 2001-05-25 2002-11-28 Bayer Ag Substituierte Benzoylketone
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
GB0118752D0 (en) * 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030066060A1 (en) 2001-09-28 2003-04-03 Ford Richard L. Cross profile guided optimization of program execution
WO2003033472A1 (en) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
US6821988B2 (en) * 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
WO2003047584A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
AU2002347336A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
EP1465632A1 (en) * 2001-12-12 2004-10-13 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
JP4202926B2 (ja) 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用
AU2002361846A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TW200301123A (en) 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
JP4498741B2 (ja) 2001-12-24 2010-07-07 アストラゼネカ アクチボラグ オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
WO2003064421A1 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine derivatives
NZ534171A (en) 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
AU2003225668A1 (en) * 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
WO2003093238A1 (en) * 2002-05-01 2003-11-13 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
JP3763414B2 (ja) 2002-10-21 2006-04-05 麒麟麦酒株式会社 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
US20080207617A1 (en) * 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
NZ539408A (en) 2002-11-04 2007-09-28 Astrazeneca Ab Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours
CA2509239A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
CA2510323A1 (en) 2002-12-18 2004-07-01 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
US7238679B2 (en) 2002-12-23 2007-07-03 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
US8176532B1 (en) * 2003-03-17 2012-05-08 Sprint Communications Company L.P. Secure access point for scada devices
KR100559180B1 (ko) * 2003-05-20 2006-03-14 김민서 조건부 거래에 따른 전자결제 방법 및 전자결제 서버
WO2005003140A1 (en) 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
WO2005005389A2 (en) 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1773826A4 (en) * 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
CA2603748A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
US7594258B2 (en) * 2005-06-27 2009-09-22 Yahoo! Inc. Access control systems and methods using visibility tokens with automatic propagation
US20080004273A1 (en) * 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
JP2012504606A (ja) 2008-10-01 2012-02-23 ラディック インスティテュート フォー キャンサー リサーチ 癌の治療方法
EP2367795A1 (en) * 2008-12-04 2011-09-28 Exelixis, Inc. Methods of preparing quinoline derivatives
CA2995880C (en) * 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
TW201118072A (en) * 2009-07-17 2011-06-01 Exelixis Inc Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20110059081A1 (en) 2009-09-09 2011-03-10 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
JP5461213B2 (ja) 2010-01-29 2014-04-02 三洋電機株式会社 空気調和装置の室外ユニット
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
US20120252840A1 (en) * 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605391A (zh) * 2022-02-21 2022-06-10 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用

Also Published As

Publication number Publication date
JP2010235631A (ja) 2010-10-21
EP2392564B1 (en) 2013-10-23
EP2392564A1 (en) 2011-12-07
AU2010204459B2 (en) 2013-06-20
US20070054928A1 (en) 2007-03-08
SI2213661T1 (sl) 2011-11-30
HK1164313A1 (en) 2012-09-21
US20200331860A1 (en) 2020-10-22
EP1673085B1 (en) 2011-11-09
US9174947B2 (en) 2015-11-03
HK1141799A1 (en) 2010-11-19
JP2017160270A (ja) 2017-09-14
ATE532782T1 (de) 2011-11-15
EP2609919A3 (en) 2014-02-26
ES2651730T3 (es) 2018-01-29
CA2537812C (en) 2013-01-22
LU92508I2 (fr) 2015-11-02
SI2210607T1 (sl) 2011-11-30
US8476298B2 (en) 2013-07-02
ATE520403T1 (de) 2011-09-15
CA2537812A1 (en) 2005-04-07
EP2392565B1 (en) 2014-03-19
HK1143068A1 (en) 2010-12-24
ES2436888T3 (es) 2014-01-07
WO2005030140A2 (en) 2005-04-07
EP2409704B1 (en) 2017-09-20
JP2010280674A (ja) 2010-12-16
JP5694501B2 (ja) 2015-04-01
US20120022065A1 (en) 2012-01-26
US8178532B2 (en) 2012-05-15
CY2014037I2 (el) 2019-07-10
PT2213661E (pt) 2011-12-15
US20140155378A9 (en) 2014-06-05
JP5185331B2 (ja) 2013-04-17
US20090170896A1 (en) 2009-07-02
ES2369652T3 (es) 2011-12-02
US8067436B2 (en) 2011-11-29
HRP20110810T1 (hr) 2011-12-31
HUS1400052I1 (hu) 2022-02-28
ES2925655T3 (es) 2022-10-19
JP5185332B2 (ja) 2013-04-17
US11124482B2 (en) 2021-09-21
PL2392565T3 (pl) 2014-08-29
JP5325173B2 (ja) 2013-10-23
HRP20140563T1 (hr) 2014-07-18
EP2213661B1 (en) 2011-07-20
EP3329918A2 (en) 2018-06-06
SI2392564T1 (sl) 2014-02-28
US20170355678A1 (en) 2017-12-14
PL2213661T3 (pl) 2011-12-30
EP2210607B1 (en) 2011-08-17
PL2210607T3 (pl) 2012-01-31
US20160185725A1 (en) 2016-06-30
JP2010235632A (ja) 2010-10-21
ATE517091T1 (de) 2011-08-15
JP2015131859A (ja) 2015-07-23
EP2609919A2 (en) 2013-07-03
EP2409704A2 (en) 2012-01-25
ES2371383T3 (es) 2011-12-30
AU2004275842B2 (en) 2010-09-02
US8497284B2 (en) 2013-07-30
HRP20140012T1 (hr) 2014-02-14
WO2005030140A3 (en) 2005-05-19
EP2392565A1 (en) 2011-12-07
HRP20110707T1 (hr) 2011-10-31
HK1256476A1 (en) 2019-09-27
CY2014037I1 (el) 2015-11-04
AU2010204461B2 (en) 2013-06-20
JP2011042686A (ja) 2011-03-03
EP2210607A1 (en) 2010-07-28
EP3329918A3 (en) 2018-08-15
US20070244116A1 (en) 2007-10-18
JP2014055190A (ja) 2014-03-27
DK2213661T3 (da) 2011-09-19
DK2392565T3 (da) 2014-05-05
NL300678I2 (enExample) 2017-01-31
FR14C0067I1 (enExample) 2014-10-17
CY1112056T1 (el) 2015-11-04
PT2210607E (pt) 2012-01-31
AU2010204459A1 (en) 2010-08-19
EP1673085A2 (en) 2006-06-28
CY1111956T1 (el) 2015-11-04
US20150376133A1 (en) 2015-12-31
US20090105299A1 (en) 2009-04-23
JP2024023447A (ja) 2024-02-21
JP5325172B2 (ja) 2013-10-23
JP2014055191A (ja) 2014-03-27
JP2021050233A (ja) 2021-04-01
BE2014C055I2 (enExample) 2023-12-14
EP2409704A3 (en) 2013-02-13
ES2466818T3 (es) 2014-06-11
AU2004275842A1 (en) 2005-04-07
US20070225307A1 (en) 2007-09-27
FR14C0067I2 (fr) 2015-11-20
JP4638436B2 (ja) 2011-02-23
JP2010265302A (ja) 2010-11-25
EP2612853A1 (en) 2013-07-10
SI2392565T1 (sl) 2014-05-30
HK1164312A1 (en) 2012-09-21
US20140155396A1 (en) 2014-06-05
JP2019070015A (ja) 2019-05-09
JP2007506777A (ja) 2007-03-22
DK2392564T3 (da) 2014-01-13
US7579473B2 (en) 2009-08-25
US20110077233A1 (en) 2011-03-31
DK2210607T3 (da) 2011-12-12
AU2010204461A1 (en) 2010-08-19
JP2014074059A (ja) 2014-04-24
EP1673085A4 (en) 2008-12-10
EP2213661A1 (en) 2010-08-04
EP3329918B1 (en) 2022-05-25
US20130252940A1 (en) 2013-09-26
US20120184523A1 (en) 2012-07-19
US20210253530A9 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
US11124482B2 (en) C-met modulators and methods of use
AU2021205066A1 (en) c-Met modulators and method of use
HK1256476B (en) C-met modulators and methods of use
HK1187896A (en) C-met modulators and methods of use
HK1143068B (en) N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
HK1164312B (en) C-met modulators and methods of use
HK1164313B (en) C-met modulators and methods of use
HK1165313B (en) C-met modulators and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160803